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Abstract
Context: Recently, a new coronavirus (SARS-CoV-2) as the cause of COVID-19 has made a global health crisis and a great challenge.
Pregnant women and fetuses are among the high-risk groups for COVID-19. In this review, we summarize studies regarding SARS-CoV-
2 virus-placenta interactions at the maternal-fetal interface by demonstrating the pathogenicity of the virus and defense methods
of the placenta.
Evidence Acquisition: In the present study, a search was done in domestic and international databases including Google Scholar,
Web of Science, PubMed, and Scopus using specific keywords (“Coronavirus” OR “COVID-19” OR “SARS-CoV-2”) AND (“Fetus” OR “Pla-
centa”) AND (“Pregnancy”), limited until August 2020. Finally, we reviewed 250 articles.
Results: Generally, the pathogenicity and the life cycle of SARS-CoV-2 and virus entry and replication methods allow the virus to pass
through the placenta, although there are hormonal and immune barriers in the placenta against SARS-CoV-2, such as placental type
interferons.
Conclusions: The SARS-CoV-2 can pass through the placenta, but there are defense methods against it.
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1. Context
Since December 2019, the COVID-19 outbreak has
turned into a significant global public health threat (1, 2).
According to studies, this disease is transmitted person-
to-person via respiratory viral droplets (3, 4), which led
to the COVID-19 pandemic. Pregnant women and fetuses
are among the high-risk groups for COVID-19. Due to the
rapid spreading of COVID-19, fetal health is a serious con-
cern. Nonetheless, sufficient data are not available regard-
ing COVID-19 evaluation and management in pregnant
women, and the possible vertical transmission risk is un-
clear (5).
The placenta, an entirely specialized organ, is vital for
normal fetus growth and development during pregnancy
(6). It supplies the fetus with oxygen and nutrients and re-
moves the wastes and carbon dioxide. Besides substance
transfer, the placenta acts as a barrier and prevents fetal ex-
posure to potentially dangerous substances in the mater-
nal blood. However, it cannot completely exclude all dan-
gerous substances and prevent fetal exposure. Moreover,
the placenta, as well as metabolizing some substances.
Nevertheless, the virus passage from the placental barrier
depends on the placental membrane’s physical properties
and the viral particle biological properties. We intended
to assess whether SARS-CoV-2 could cross the placenta. For
this purpose, SARS-CoV-2 entry, pathogenicity, and replica-
tion methods were discussed in addition to the placental
defense methods. Substantial research and time are re-
quired to understand how this virus may involve the fetus.
2. The Life Cycle of SARS-CoV-2 and the Pathogen Char-
acteristics
2.1. Morphology, Structure, and Stability of SARS-CoV-2
The large pleomorphic spherical coronavirus particles
have surface crown-like projections. The coronavirus di-
ameter ranges from 75 nm to 160 nm (an average of 120
nm) (7, 8). The virion of SARS-CoV-2 is spherical and has a
mean diameter of 78 nm. A lipid bilayer covers this virus
where the envelope (E), membrane (M), and spike (S) struc-
tural proteins are located. As a beta coronavirus subset,
SARS-CoV-2 has shorter spike-like surface proteins, which
are known as hemagglutinin esterase (HE) (9). A nucleo-
capsid is inside the envelope, which is formed by several
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copies of nucleocapsid (N) proteins, which are attached
to the single-stranded positive-sense RNA genome in an
uninterrupted beads-on-a-string type shape. The genome
length ranges between 26 and 32 kilobases (kb), which is
the largest genome among the RNA viruses. This genome
codes two proteases (polyproteins) (10).
Usually, its molecular weight is 5.5 - 6.1 × 106 (11). The
membrane proteins, lipid bilayer envelope, and nucleo-
capsid protect this virus out of the host cell. Coronaviruses
are stable at 4°C, room temperature (20°C,) and 37°C for a
minimum of 2 h without a significant change in their in-
fectious ability. However, they are noninfectious when ex-
posed to 56°C, 67°C, and 75°C for 90, 60, and 30 min, respec-
tively. Sixty minutes of UV irradiation destroys the viral in-
fectivity in the culture medium at an undetectable level.
Evidence suggests the great survival of the coronavirus
in the environment and human specimens. It should be
noted that UV irradiation and heating are effective meth-
ods for the eradication of viral infectivity (12, 13).
2.2. Pathogenicity and Entry Methods of SARS-CoV-2
First, the virus should cross the cell membrane, which
is rich in cholesterol and sphingolipid. The SARS-CoV-2 en-
velope should be bound to the membrane of the host cell
for delivering the nucleocapsid to the host cell. Thanks to
specific domains of protein S, SARS-CoV-2 binds to the sur-
face molecules of the cell. The virus entry is mediated by
the spike (S) glycoprotein, which is a key factor and known
as the SARS-CoV-2 cell receptor, and plays a significant role
in disease transmission and human infection (Figure 1)
(14).
Using receptor binding, proteolytic activation, and low
pH exposure, the protein S shape is changed for cell en-
try (15). Cathepsin L, a protease associated with endoso-
mal membranes, promotes viral infectivity through trans-
forming the uncleaved S polypeptides to S1 and S2 proteins.
Multiple strategies are available for spike protein prote-
olytic activation, such as cell surface transmembrane pro-
tease/serine (TMPRSS) proteases, trypsin, and furin. The
host cell serine protease TMPRSS2 primes the SARS-CoV-2 S
protein for cell entry (16, 17).
2.3. Replication
After cell entry, SARS-CoV-2 should replicate in the cy-
toplasm in which viral RNA is replicated (18). Replicase, a
viral RNA polymerase, is the first gene that is translated,
which produces negative-strand full-length copies of the
genome to provide mRNAs for the viral genes. In an in-
fected cell with SARS-CoV-2, large granular areas may be de-
tected, which contain viral RNA and proteins. The viral par-
ticles are collected in the Golgi body and vesicles, where
the virus particles are transferred to the surface of the cell
to be released by exocytosis (Figure 1) (19).
3. Defense Methods of Placenta
3.1. Physicochemical and Structural Properties of Placenta
Against SARS-CoV-2
As a mediator between the fetus and mother, the pla-
centa plays several vital roles. It prevents fetal allograft
rejection, protects the fetus, exchanges the nutrients and
respiratory gases, removes fetal waste products, and re-
leases steroid and peptide hormones, which are crucial
for fetus growth and development. The placenta syncy-
tiotrophoblast layer is a major site for respiratory gas and
nutrient exchange between the fetus and the maternal
bloodstream (Figure 2) (20, 21). Several mechanisms are
involved in this exchange: endocytosis, exocytosis, tran-
scellular transfer (22), simple diffusion (23), and solvent
drag (24). A receptor may mediate exocytosis and endo-
cytosis processes, which is stimulated by a specific solute-
receptor interaction on the cellular membrane (25). The
transfer is affected by many factors, including the surface
area, thickness, and metabolism of the planta, as well as fe-
tal and maternal blood pH, uteroplacental blood flow, vi-
ral molecular weight, presence of viral transporters of the
placenta, protein binding, lipid solubility, cross-placental
concentration gradient, degree of ionization, and molecu-
lar weight (20, 26).
With a molecular weight of 5.5 - 6.1 × 106, SARS-CoV-2
may cross the placenta through the endocytosis process.
The average chorionic artery pH is 7.31 (27). As known, SARS-
CoV-2 requires a low pH for cell endosomal entry. The re-
ceptor of SARS-CoV-2, ACE2, is widespread in the cells of the
maternal-fetal interface such as stromal cells, placental cy-
totrophoblast, and syncytiotrophoblast, as well as perivas-
cular cells of the decidua. The high ACE2 expression in
these cells shows that the placenta may be potentially in-
fected with SARS-CoV-2 (28). Proteases, such as TMPRSS2,
are required for the conformational change of protein S.
Besides, TMPRSS2 mRNA expression is reported in the pla-
centa (29).
The polymerase is required for SARS-CoV-2 replication.
Three kinds of polymerases are present in the placenta. The
activity of them is high in early pregnancy due to placental
formation and mitosis, though it is low during the second
trimester. The polymerase β activity does not change re-
markably during pregnancy (30).
3.2. Hormonal and Immune Protection of the Placenta
de Goffau et al. (31) failed to find supporting evidence
for the presence of the placental microbiome. However,
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Figure 1. SARS-CoV-2 Life cycle and pathogenicity in nine stages; the virus-cell entry through the endocytosis process via ACE2 receptors; viral replication by polymerase and
producing negative-strand full-length copies of the genome to provide mRNAs for the viral genes; viral particle gathering in the Golgi; viral particle release by exocytosis
(figure was made using biorender.com).
they recognized a significant pathogen, S. agalactiae, in the
placenta of nearly 5% of women before labor onset (31). The
placenta is a tough immune organ by itself. When exposed
to pathogens, it expresses pattern recognition receptors
(PRR) and, in this way, responds to pathogens at the fetal-
maternal interface (32, 33).
A study showed that SARS-CoV-2 pathogenesis is mainly
caused by the inflammatory response (34). The innate
immune system is the first line of defense against this
pathogen. The most significant immunomodulators are
the placental type interferons (IFNs), which support preg-
nancy. In the case of a viral infection, interferons I and III
function as the antiviral defense responses (35, 36). The in-
terferon I antiviral activity directly inhibits the replication
of the virus. It also mediates both innate and adaptive cel-
lular immune functions to produce resistance against viral
infections and manage long-term immunity. Interferons I
and III are strong placental antiviral proteins (Figure 2) (37-
39).
Some viruses can inhibit the interferon I pathway and
thus lead to the replication of the virus and infection. A
great deal of the structural, nonstructural, and accessory
proteins of coronaviruses have been shown to antagonize
the response of IFNs. Besides the proteins, the genome of
the coronavirus also encodes non-coding RNAs (ncRNAs).
An N gene small ncRNA inhibition has been associated with
reduced inflammation (40). These data are in line with the
hypothesis stating that SARS-CoV-2 may potentially cross
the placenta (Figure 3). Yet, can the crossed virus cause fe-
tal infection? SARS-CoV-2 is a novel and an unknown virus.
Many studies are required to further learn about SARS-CoV-
2.
4. Evidence Supporting SARS-CoV-2 Crossing the Pla-
centa
The Zeng et al. (41) study of antibodies in the infants
of mothers suffering from COVID-19 pneumonia demon-
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Figure 2. Placental barrier, immunological and physical defenses (figure was made using biorender.com).
strated elevated IgG levels in five infants and IgM detection
in two infants at birth. Although IgG antibodies passively
transfer across the placenta, IgM antibodies do not usu-
ally cross the placenta due to their larger molecular sizes.
Hence, IgM might have been synthesized by the infant in
the case of the SARS-CoV-2 cross (41). In another study, Al-
garroba et al. (42) identified coronavirus virions invading
syncytiotrophoblasts in placental villi by using electron
microscopy in a woman at 28 weeks’ gestation due to se-
vere COVID-19 infection. Vivanti et al. (43) demonstrated
the transplacental transmission of SARS-CoV-2 in a neonate
born to a mother infected in the last trimester presenting
with neurological compromise, confirmed by comprehen-
sive virological and pathological investigations.
5. Evidence Against SARS-CoV-2 Crossing the Placenta
The only published study on the placental pathology
of seven pregnant women with SARS-CoV-2 was conducted
by Ng et al. (44), which reported abnormal placenta in
the acute phase of COVID-19, as well as COVID-19 cases in
the third trimester. The pathology reports indicated ele-
vated intervillous and subchorionic fibrin and diffuse fetal
thrombotic vasculopathy in the avascular chorionic villi
areas. Interestingly, villitis, as an important manifesta-
tion of placental inflammation, was not recognized. Villi-
tis is a major histologic sign in various maternal infections,
which are hematogenously transmitted to the fetus via the
placenta (44).
Schwartz (45) investigated 38 pregnant women who
suffered from COVID-19. They reported that SARS-CoV-2 was
not transmitted through the intrauterine or transplacen-
tal routes from infected pregnant women to the fetuses
(45). They reported two neonatal COVID-19 cases, both of
which failed to provide sufficient evidence to prove ver-
tical transmission due to delayed testing or the potential
transmission through a postpartum-infected contact (46,
47). Also, Chen et al. (48) did not report any evidence of
positive COVID-19 diagnostic tests or symptoms in the in-
fants of symptomatic, test-positive mothers. In another pa-
per (letter to the editor), Kniss (49) proposed that the struc-
tures identified by Algarroba et al. are clathrin-coated vesi-
cles, not SARS-CoV-2 particles (42).
6. Conclusions
A very serious complication of viral infections during
pregnancy is vertical transmission. Except for the her-
pes virus, the maternal-fetal transmission of viral diseases
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Figure 3. SARS-CoV-2 requirements for crossing the placenta and function of the placenta
commonly occurs via the hematogenous route. Terato-
genicity and fetal growth and development impairment
are among the known adverse effects of viral transplacen-
tal passage. This highlights the significance of investigat-
ing potential placental involvement in pregnant women
who are infected with SARS- CoV-2.
Although the data is in line with the hypothesis of the
SARS-COV-2 passage through the placenta, the placental de-
fense system protects clinically against significant placen-
tal infection. It should be noted that intrauterine fetal
growth restriction and maternal comorbidities, including
gestational diabetes and preeclampsia, may damage the
placental barrier by several mechanisms such as abnormal
cytotrophoblast differentiation, defective placental angio-
genesis, and placental ischemia. These mechanisms in-
crease the risk of SARS-CoV-2 intrauterine transmission to
the fetus. The growing knowledge of the placental defense
mechanisms, as well as the immunological and hormonal
responses, may help develop new antiviral agents.
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